Arcus Biosciences (RCUS) director receives RSU and stock option awards
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Arcus Biosciences, Inc. director Yasunori Kaneko reported new equity awards and updated indirect holdings of Common Stock. On June 11, 2026, he received 5,700 restricted stock units, which vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders, and accelerate upon a change in control. He also received a stock option for 16,900 shares at an exercise price of $23.30 per share, vesting on the same schedule and also accelerating upon a change in control. Following these awards, he holds 25,700 shares of Common Stock directly, and indirect holdings include 174,681 shares by trust, 505,050 shares by Kaneko Capital, LLC, and 252,524 shares by Kaneko Investments, LLC. A footnote notes 13,300 previously reported RSUs vested on June 11, 2026 and were transferred to his trust.
Positive
- None.
Negative
- None.
Insider Trade Summary
5 transactions reported
Mixed
5 txns
Insider
KANEKO YASUNORI
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 16,900 | $0.00 | -- |
| Grant/Award | Common Stock | 5,700 | $0.00 | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 16,900 shares (Direct, null);
Common Stock — 25,700 shares (Direct, null);
Common Stock — 252,524 shares (Indirect, By Kaneko Investments, LLC)
Footnotes (1)
- Represents the grant of restricted stock units that vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders of the issuer. The RSUs will become fully vested in the event the Company is subject to a change in control. Includes 13,300 shares of restricted stock units (previously reported) that vested on June 11, 2026 and were subsequently transferred to the reporting person's trust. The option will vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders of the issuer. The option will become fully vested and exercisable in the event the Company is subject to a change in control.
Key Figures
RSU grant size: 5,700 units
Option grant size: 16,900 shares
Option exercise price: $23.30 per share
+5 more
8 metrics
RSU grant size
5,700 units
Restricted stock units granted on June 11, 2026
Option grant size
16,900 shares
Stock option granted on June 11, 2026
Option exercise price
$23.30 per share
Exercise price for 16,900-share option expiring June 10, 2036
Direct common shares
25,700 shares
Common Stock held directly following transactions
Trust-held shares
174,681 shares
Common Stock held indirectly by trust
Kaneko Capital, LLC shares
505,050 shares
Common Stock held indirectly by Kaneko Capital, LLC
Kaneko Investments, LLC shares
252,524 shares
Common Stock held indirectly by Kaneko Investments, LLC
Previously vested RSUs
13,300 units
RSUs that vested June 11, 2026 and moved to trust
Key Terms
restricted stock units, change in control, stock option, annual meeting of stockholders, +1 more
5 terms
restricted stock units financial
"Represents the grant of restricted stock units that vest in full on the earlier of June 11, 2027 or the next annual meeting"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
change in control financial
"The RSUs will become fully vested in the event the Company is subject to a change in control"
A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.
stock option financial
"The option will vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders of the issuer"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
annual meeting of stockholders financial
"vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders of the issuer"
indirect ownership financial
"direct_or_indirect: "I", nature_of_ownership: "By Trust""
FAQ
What equity awards did Yasunori Kaneko receive from Arcus Biosciences (RCUS)?
Yasunori Kaneko received 5,700 restricted stock units and a stock option for 16,900 shares at an exercise price of $23.30 per share. Both awards vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders.
When do Yasunori Kaneko’s new Arcus Biosciences equity awards vest?
Both the 5,700 restricted stock units and the 16,900-share stock option vest in full on the earlier of June 11, 2027 or the next Arcus Biosciences annual stockholder meeting. They also become fully vested if the company experiences a change in control, according to the disclosure.
What is the exercise price and term of Yasunori Kaneko’s new stock option at RCUS?
The new stock option covers 16,900 shares of Arcus Biosciences Common Stock at an exercise price of $23.30 per share. It expires on June 10, 2036 and will vest in full on the earlier of June 11, 2027 or the next annual stockholder meeting.
What happened to Yasunori Kaneko’s previously reported restricted stock units at Arcus Biosciences?
A footnote states that 13,300 previously reported restricted stock units vested on June 11, 2026 and were subsequently transferred to Yasunori Kaneko’s trust. These vested RSUs are now reflected within his indirect holdings reported as being held by the trust in the ownership table.
How does a change in control affect Kaneko’s new Arcus Biosciences awards?
Both the 5,700 RSUs and the 16,900-share stock option become fully vested if Arcus Biosciences is subject to a change in control. This means vesting would accelerate upon such an event, rather than following only the scheduled vesting dates disclosed for these awards.